期刊文献+

慢性阻塞性肺疾病患者呼出气一氧化氮测定的临床意义 被引量:13

Clinical significance of measuring fractional exhaled nitric oxide in patients with chronic obstructive pulmonary disease
下载PDF
导出
摘要 目的观察慢性阻塞性肺疾病(COPD)患者呼出气一氧化氮(FENO)的变化及其临床意义。方法分别测定25例健康对照组、25例COPD急性发作期(AECOPD)患者治疗前、后的FENO值,AECOPD组患者治疗前后分别测定肺功能(FEV1绝对值、FEV1%预计值)。结果①AECOPD组治疗前FENO值明显高于健康对照组(24.4±5.11 vs 16.97±3.78,P<0.01),治疗后与治疗前比较FENO值明显下降(18.3±2.76 vs 24.4±5.11,P<0.01),但治疗后FENO值与健康对照组差异无统计学意义(18.3±2.76 vs 16.97±3.78,P=0.245);②AECOPD患者治疗前后FENO值与肺功能FEV1、FEV1%高低均无明显相关性(P>0.05)。结论 AECOPD时NO生成及释放增多,测定FENO的升高可提示存在气道炎症,可用于预测患者抗炎治疗的效果。 Objective To evaluate the clinical significance of fractional exhaled nitric oxide (FENO) in patients with chronic obstructive pulmonary disease (COPD). Methods FENO values in 25 cases of healthy control group, 25 cases of acute exacerbation of COPD (AECOPD) group before and after the treatment were measured respectively. The FEV1, FEV1% pred were measured before and after AECOPD treatment. Results ①FENO values in AECOPD patients before treatment were significantly higher than those in healthy control group (24.4 ± 5.11 vs 16.97 ± 3.78, P 〈 0.01, and decreased significantly after treatment (24.4 ± 5.11 vs 18.3 ± 2.76, P 〈 0.01 ). However, there was no significant difference between healthy controls and AECOPD patients after treatment ( 16.97 ± 3.78 vs 18.3 ± 2.76, P = 0. 245). ②FENO values in AECOPD patients were not significantly correlated with FEV1, FEV1% level of lung function before and after treatment ( P 〉 0.05 ). Conclusion FENO can be considered as a marker of airway infla ammation, and used in forecasting the effect of anti -inflammatory therapy in patients.
作者 刘红艳 赵卉
出处 《安徽医学》 2013年第8期1115-1117,共3页 Anhui Medical Journal
关键词 慢性阻塞性肺疾病 呼出气一氧化氮 肺功能 Chronic obstructive pulmonary disease Fractional exhaled nitric oxide Lung function
  • 相关文献

参考文献12

二级参考文献20

  • 1李靖,郑劲平,袁锦屏,杨灵,罗锭芬,安嘉颍,肖正伦,钟南山,钟维农,何为国,赵子文,曾军,林材元.口服八种细菌提取物对慢性支气管炎合并慢性阻塞性肺疾病急性加重的预防作用[J].中华结核和呼吸杂志,2004,27(9):631-633. 被引量:29
  • 2GOLD Executive Committee. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease ( Revised 2011 ). www. goldeopd, com.
  • 3朱元钰 陈文彬.呼吸病学[M].北京:人民卫生出版社,2003.7-9.
  • 4Clini E,Cremona G,Campana M,et al. Production of endogenous nitric oxide in chronic obstructive pulmonary disease and patients with cor pulmonale:correlates with echo-Doppler assessment. Am J Respir Crit Care Med,2000,162:446-450.
  • 5Corradi M, Pesci A, Casana R, et al. Nitrate in exhaled breath condensate of patients with different airway diseases. Nitric Oxide,2003,8:26-30.
  • 6Biernacki WA, Kharitonov SA, Barnes PJ. Increased leukotriene B4 and 8-isoprostane in exhaled breath condensate of patients with exacerbations of COPD. Thorax, 2003,58 :294-298.
  • 7Carpagnano GE, Resta O, Foschino-Barbaro MP, et al. Exhaled Interleukine-6 and 8-isoprostane in chronic obstructive pulmonary disease:effect of carbocysteine lysine salt monohydrate (SCMCLys). Eur J Pharmacol,2004,505 : 169-175.
  • 8Schulz C, WoIf K, Harth M, et al. Expression and release of interleukin-8 by human bronchial epithelial cells from patients with chronic obstructive pulmonary disease, smokers, and neversmokers. Respiration, 2003,70 :254-261.
  • 9Hunt JF, Fang K, Malik R, et al. Endogenous airway acidification: implications for asthma pathophysiology. Am J Respir Crit Care Med,2000,161 :694-699.
  • 10中华医学会呼吸病学会.慢性阻塞性肺疾病诊治规范[J].中华结核和呼吸杂志,2006,23(1):1-1.

共引文献727

同被引文献88

引证文献13

二级引证文献93

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部